Quick Answer
Orthofix Medical Inc. reported Total Revenue of $822.31 million for fiscal year 2025.
Orthofix Medical Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $822.31M +2.9% |
$799.49M +7.1% |
$746.64M +62.1% |
$460.71M -0.8% |
$464.48M +14.2% |
$406.56M -11.6% |
| Revenue (ASC 606) | $822.31M +2.9% |
$799.49M +7.1% |
$746.64M +62.1% |
$460.71M -0.8% |
$464.48M +14.2% |
$406.56M -11.6% |
| Net Income | -$92.19M +26.8% |
-$126.00M +16.8% |
-$151.40M -666.6% |
-$19.75M +48.5% |
-$38.38M -1624.8% |
$2.52M +108.8% |
| Diluted EPS | -$2.33 +29.4% |
-$3.30 +19.9% |
-$4.12 -320.4% |
-$0.98 +49.7% |
-$1.95 -1600.0% |
$0.13 +108.6% |
| Total Assets | $850.65M -4.8% |
$893.29M -3.5% |
$925.32M +101.8% |
$458.63M -3.8% |
$476.62M -9.4% |
$525.86M +6.1% |
| Cash and Equivalents | $82.03M -1.5% |
$83.24M +151.4% |
$33.11M -34.7% |
$50.70M -42.3% |
$87.85M -8.8% |
$96.29M +38.1% |
| Long-Term Debt | $157.39M +0.2% |
$157.01M +68.6% |
$93.11M | — | — | — |
| Stockholders Equity | $450.04M -10.6% |
$503.12M -16.0% |
$598.73M +77.7% |
$336.86M -0.0% |
$336.93M -5.6% |
$356.86M +8.9% |
| R&D Expense | $65.85M -10.6% |
$73.64M -8.2% |
$80.23M +63.5% |
$49.06M -1.1% |
$49.62M +27.1% |
$39.06M +12.8% |
| Operating Income | -$81.43M +3.8% |
-$84.62M +39.2% |
-$139.11M -948.5% |
-$13.27M -59.6% |
-$8.31M -32.7% |
-$6.27M +66.6% |
| Gross Profit | $566.02M +3.7% |
$545.88M +12.3% |
$486.27M +44.2% |
$337.17M -3.5% |
$349.56M +14.7% |
$304.67M -15.2% |
| Shares Outstanding | 39.83M +3.5% |
38.49M +3.6% |
37.16M +84.3% |
20.16M +1.6% |
19.84M +2.1% |
19.42M +2.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $205.63M | +4.6% | +1.2% |
| Revenue (ASC 606) | September 30, 2025 | $205.63M | +4.6% | +1.2% |
| Net Income | September 30, 2025 | -$22.80M | +16.8% | -61.9% |
| Diluted EPS | September 30, 2025 | -$0.57 | +19.7% | -58.3% |
| Total Assets | September 30, 2025 | $832.61M | -4.1% | -0.5% |
| Cash and Equivalents | September 30, 2025 | $62.86M | +109.2% | -4.2% |
| Long-Term Debt | September 30, 2025 | $157.22M | +40.1% | +0.1% |
| Stockholders Equity | September 30, 2025 | $442.49M | -15.9% | -3.5% |
| R&D Expense | September 30, 2025 | $14.77M | -14.6% | -7.3% |
| Operating Income | September 30, 2025 | -$17.05M | +9.8% | -6.5% |
| Gross Profit | September 30, 2025 | $148.52M | +10.0% | +6.4% |
| Shares Outstanding | September 30, 2025 | 39.52M | +3.4% | +0.1% |
- Orthofix Medical Inc. reported Total Revenue of $822.31 million for fiscal year 2025.
- Orthofix Medical Inc. showed an increase of +2.9% in Total Revenue compared to the prior fiscal year.
- Orthofix Medical Inc. reported Revenue (ASC 606) of $822.31 million for fiscal year 2025.
- Orthofix Medical Inc. showed an increase of +2.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Orthofix Medical Inc. reported Net Income of -$92.19 million for fiscal year 2025.
- Orthofix Medical Inc. showed an increase of +26.8% in Net Income compared to the prior fiscal year.
- Orthofix Medical Inc. reported Diluted EPS of $2.33 per share (loss) for fiscal year 2025.
- Orthofix Medical Inc. showed an increase of +29.4% in Diluted EPS compared to the prior fiscal year.
- Orthofix Medical Inc. reported Total Assets of $850.65 million for fiscal year 2025.
- Orthofix Medical Inc. showed a decrease of -4.8% in Total Assets compared to the prior fiscal year.
- Orthofix Medical Inc. reported Cash and Equivalents of $82.03 million for fiscal year 2025.
- Orthofix Medical Inc. showed a decrease of -1.5% in Cash and Equivalents compared to the prior fiscal year.
- Orthofix Medical Inc. reported Long-Term Debt of $157.39 million for fiscal year 2025.
- Orthofix Medical Inc. showed an increase of +0.2% in Long-Term Debt compared to the prior fiscal year.
- Orthofix Medical Inc. reported Stockholders Equity of $450.04 million for fiscal year 2025.
- Orthofix Medical Inc. showed a decrease of -10.6% in Stockholders Equity compared to the prior fiscal year.
- Orthofix Medical Inc. reported R&D Expense of $65.85 million for fiscal year 2025.
- Orthofix Medical Inc. showed a decrease of -10.6% in R&D Expense compared to the prior fiscal year.
- Orthofix Medical Inc. reported Operating Income of -$81.43 million for fiscal year 2025.
- Orthofix Medical Inc. showed an increase of +3.8% in Operating Income compared to the prior fiscal year.
- Orthofix Medical Inc. reported Gross Profit of $566.02 million for fiscal year 2025.
- Orthofix Medical Inc. showed an increase of +3.7% in Gross Profit compared to the prior fiscal year.
- Orthofix Medical Inc. reported Shares Outstanding of 39.83 million shares for fiscal year 2025.
- Orthofix Medical Inc. showed an increase of +3.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: